Abstract
Background: We are aware of no study that has indicated the effects of daily consumption of multispecies probiotic supplements on metabolic profiles, high-sensitivity C-reactive protein (hs-CRP), and oxidative stress in diabetic patients. Objective: This study was designed to determine the effects of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in diabetic patients. Methods: This randomized double-blind placebo-controlled clinical trial was performed on 54 diabetic patients aged 35-70 years. Subjects were randomly assigned to take either a multispecies probiotic supplement (n = 27) or placebo (n = 27) for 8 weeks. The multispecies probiotic supplement consisted of 7 viable and freeze-dried strains: Lactobacillus acidophilus (2 × 109 CFU), L. casei (7 × 109 CFU), L. rhamnosus (1.5 × 109 CFU), L. bulgaricus (2 × 108 CFU), Bifidobacterium breve (2 × 1010 CFU), B. longum (7 × 109 CFU), Streptococcus thermophilus (1.5 × 109 CFU), and 100 mg fructo-oligosaccharide. Fasting blood samples were taken at baseline and after intervention to measure metabolic profiles, hs-CRP, and biomarkers of oxidative stress including plasma total antioxidant capacity and total glutathione (GSH). Results: Between-group comparisons of fasting plasma glucose (FPG) revealed that consumption of probiotic supplements prevented a rise in FPG (+28.8 ± 8.5 for placebo vs. +1.6 ± 6 mg/dl for probiotic group, p = 0.01). Although a significant within-group increase in serum insulin and low-density lipoprotein cholesterol levels was found in both the probiotic group and the placebo group, the changes were similar between the two groups. We observed a significant increase in HOMA-IR (homeostasis model of assessment-insulin resistance) in both the probiotic group (p = 0.02) and the placebo group (p = 0.001); however, the increase in the placebo group was significantly higher than that in the probiotic group (+2.38 vs. +0.78, p = 0.03). Mean changes in serum hs-CRP were significantly different between the two groups (-777.57 for the probiotic group vs. +878.72 ng/ml for the placebo group, p = 0.02). Probiotic supplementation led to a significant increase in plasma GSH levels compared to placebo (240.63 vs. -33.46 µmol/l, p = 0.03). Conclusion: In conclusion, multispecies probiotic supplementation, compared with placebo, for 8 weeks in diabetic patients prevented a rise in FPG and resulted in a decrease in serum hs-CRP and an increase in plasma total GSH.
Journal Section:
Original Paper
References
1.
Yan L, Hui G: Subcutaneous implanted system for the treatment of type 2 diabetes. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011;33:473-477.
[PubMed]
2.
Neumann A, Schwarz P, Lindholm L: Estimating the cost-effectiveness of lifestyle intervention programmes to prevent diabetes based on an example from Germany: Markov modelling. Cost Eff Resour Alloc 2011;9:17.
[PubMed]
3.
Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR: Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J 2009;15:591-599.
[PubMed]
4.
Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, et al: Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010;2010:592760.
[PubMed]
5.
Yadav H, Jain S, Sinha PR: Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007;23:62-68.
[PubMed]
6.
Shim U, Lee H, Oh JY, Sung YA: Sleep disorder and cardiovascular risk factors among patients with type 2 diabetes mellitus. Korean J Intern Med 2011;26:277-284.
[PubMed]
7.
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, et al: The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-190, 215-357, iii-iv.
[PubMed]
8.
Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S: Exercise for the management of type 2 diabetes: a review of the evidence. Acta Diabetol 2010;47:15-22.
[PubMed]
9.
Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, et al: Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 2012;55:1544-1553.
[PubMed]
10.
Abdulkadir AA, Thanoon IA: Comparative effects of glibenclamide and metformin on C-reactive protein and oxidant/antioxidant status in patients with type II diabetes mellitus. Sultan Qaboos Univ Med J 2012;12:55-61.
[PubMed]
11.
Undas A, Ariens RA: Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011;31:e88-e99.
[PubMed]
12.
Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT: The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci 2009;10:3755-3775.
[PubMed]
13.
Mallappa RH, Rokana N, Duary RK, Panwar H, Batish VK, Grover S: Management of metabolic syndrome through probiotic and prebiotic interventions. Indian J Endocrinol Metab 2012;16:20-27.
[PubMed]
14.
Kullisaar T, Songisepp E, Mikelsaar M, Zilmer K, Vihalemm T, Zilmer M: Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects. Br J Nutr 2003;90:449-456.
[PubMed]
15.
Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V: Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012;28:539-543.
[PubMed]
16.
Lambert JM, Bongers RS, de Vos WM, Kleerebezem M: Functional analysis of four bile salt hydrolase and penicillin acylase family members in Lactobacillus plantarum WCFS1. Appl Environ Microbiol 2008;74:4719-4726.
[PubMed]
17.
Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Adrio JL, et al: Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis 2006;21:737-746.
[PubMed]
18.
Kullisaar T, Zilmer M, Mikelsaar M, Vihalemm T, Annuk H, Kairane C, et al: Two antioxidative Lactobacilli strains as promising probiotics. Int J Food Microbiol 2002;72:215-224.
[PubMed]
19.
Hegazy SK, El-Bedewy MM: Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010;16:4145-4151.
[PubMed]
20.
Tabuchi M, Ozaki M, Tamura A, Yamada N, Ishida T, Hosoda M, et al: Antidiabetic effect of Lactobacillus GG in streptozotocin-induced diabetic rats. Biosci Biotechnol Biochem 2003;67:1421-1424.
[PubMed]
21.
Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H: Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002;76:1249-1255.
[PubMed]
22.
Zhang JW, Du P, Chen DW, Cui L, Ying CM: Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer (in Chinese). Zhonghua Wei Chang Wai Ke Za Zhi 2010;13:40-43.
[PubMed]
23.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35:S64-S71.
[PubMed]
24.
Erel O: A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-285.
[PubMed]
25.
Surapaneni KM, Venkataramana G: Status of lipid peroxidation, glutathione, ascorbic acid, vitamin E and antioxidant enzymes in patients with osteoarthritis. Indian J Med Sci 2007;61:9-14.
[PubMed]
26.
Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070.
[PubMed]
27.
White JR Jr: Economic considerations in treating patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2002;59:S14-S17.
[PubMed]
28.
St-Onge MP, Farnworth ER, Savard T, Chabot D, Mafu A, Jones PJ: Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial (ISRCTN10820810). BMC Complement Altern Med 2002;2:1.
[PubMed]
29.
Ooi LG, Liong MT: Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 2010;11:2499-2522.
[PubMed]
30.
Cavallini DC, Bedani R, Bomdespacho LQ, Vendramini RC, Rossi EA: Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study. Lipids Health Dis 2009;8:1.
[PubMed]
31.
Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, et al: Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011;110:650-657.
[PubMed]
32.
Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007;50:2374-2383.
[PubMed]
33.
Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350.
[PubMed]
34.
Musso G, Gambino R, Cassader M: Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 2010;33:2277-2284.
[PubMed]
35.
Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al: Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22:2416-2426.
[PubMed]
36.
Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, et al: S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc Natl Acad Sci USA 2008;105:19474-19479.
[PubMed]
37.
Ouwehand AC, Tiihonen K, Saarinen M, Putaala H, Rautonen N: Influence of a combination of Lactobacillus acidophilus NCFM and lactitol on healthy elderly: intestinal and immune parameters. Br J Nutr 2009;101:367-375.
[PubMed]
38.
Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, et al: Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 2011;94:3288-3294.
[PubMed]
39.
Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K: Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis 2012;11:29.
[PubMed]
40.
Lewis S, Burmeister S, Cohen S, Brazier J, Awasthi A: Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;21:469-477.
[PubMed]
41.
Greany KA, Bonorden MJ, Hamilton-Reeves JM, McMullen MH, Wangen KE, Phipps WR, et al: Probiotic capsules do not lower plasma lipids in young women and men. Eur J Clin Nutr 2008;62:232-237.
[PubMed]
42.
Ribas V, Nguyen MT, Henstridge DC, Nguyen AK, Beaven SW, Watt MJ, et al: Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice. Am J Physiol Endocrinol Metab 2010;298:E304-E319.
[PubMed]
43.
Kiessling G, Schneider J, Jahreis G: Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr 2002;56:843-849.
[PubMed]
44.
Smedman AE, Gustafsson IB, Berglund LG, Vessby BO: Pentadecanoic acid in serum as a marker for intake of milk fat: relations between intake of milk fat and metabolic risk factors. Am J Clin Nutr 1999;69:22-29.
[PubMed]
45.
Anderson AD, McNaught CE, Jain PK, MacFie J: Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004;53:241-245.
[PubMed]
46.
Asemi Z, Jazayeri S, Najafi M, Samimi M, Mofid V, Shidfar F, et al: Effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women: a randomized controlled trial. Pak J Biol Sci 2011;14:476-482.
[PubMed]
47.
Hatakka K, Martio J, Korpela M, Herranen M, Poussa T, Laasanen T, et al: Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis - a pilot study. Scand J Rheumatol 2003;32:211-215.
[PubMed]
48.
Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, et al: Perioperative symbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006;244:706-714.
[PubMed]
49.
Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, et al: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54:242-249.
[PubMed]
50.
Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R: Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin 2009;25:1919-1930.
[PubMed]
51.
Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, Jalali M, Heshmat R, Chamary M: The effects of probiotic and conventional yoghurt on lipid profile in women. Br J Nutr 2010;103:1778-1783.
[PubMed]
52.
Kullisaar T, Songisepp E, Aunapuu M, Kilk K, Arend A, Mikelsaar M, et al: Complete glutathione system in probiotic Lactobacillus fermentum ME-3. Prikl Biokhim Mikrobiol 2010;46:527-531.
[PubMed]
53.
Lutgendorff F, Trulsson LM, van Minnen LP, Rijkers GT, Timmerman HM, Franzen LE, et al: Probiotics enhance pancreatic glutathione biosynthesis and reduce oxidative stress in experimental acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2008;295:G1111-G1121.
[PubMed]
54.
Asemi Z, Jazayeri S, Najafi M, Samimi M, Mofid V, Shidfar F, et al: Effect of daily consumption of probiotic yogurt on oxidative stress in pregnant women: a randomized controlled clinical trial. Ann Nutr Metab 2012;60:62-68.
[PubMed]
55.
Hashem MA, Mohamed MH: Haemato-biochemical and pathological studies on aflatoxicosis and treatment of broiler chicks in Egypt. Vet Ital 2009;45:323-337.
[PubMed]
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.
